FindTrial
Sign In

Establishment and evaluation of a prediction model for the risk of hemorrhage and ischemia caused by ticagrelor

Establishment and evaluation of a prediction model for the risk of hemorrhage and ischemia caused by ticagrelor

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075627
Enrollment
Unknown
Registered
2023-09-11
Start date
2023-09-11
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disease

Interventions

Whether there has been a bleeding event:NA

Sponsors

Zhongshan Hospital (Xiamen), Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? at least 18 years old; ? Tiagrelor should be treated for 6 months; ? Approved by the Ethics committee;

Exclusion criteria

Exclusion criteria: Patients with malignant tumors, high blood pressure (180/110mmHg), heart failure, severe cardiovascular and cerebrovascular diseases, long-term diarrheal diseases, or pregnant or lactating women; History of bleeding and/or thrombosis before taking the drug; (3) Past and present liver disease, or serum transaminase greater than 1.5 times normal; ? Impaired renal function, serum creatinine > 120µmol/L; ? Data cannot be obtained for other reasons.

Design outcomes

Primary

MeasureTime frame
Bleeding event;Ischemic event;Readmission rate;—

Countries

China

Contacts

Public ContactXia Xiaotong

Zhongshan Hospital (Xiamen), Fudan University ,

xia.xiaotong@zsxmhospital.com+86 159 8022 6589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026